Project Grant R21AI182953
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$235K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baton Rouge, LA 70803, USA
Similar Awards
This $837,644 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop an effective vaccine targeting poly-b-(1-6)-N-acetylglucosamine (PNAG), a key virulence factor present on many non-viral pathogens. The research team will establish new methodologies to synthesize a comprehensive library of PNAG glycans with varied amine/acetylation patterns, covalently...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel vaccine candidate against multi-drug resistant Acinetobacter baumannii (MDR-AB). The $288,360 grant, awarded on Dec 23, 2024, will fund research by Biological Mimetics, Inc. to (1) identify key immunogenic components of MDR-AB, (2) develop a prototype vaccine formulation, and (3) conduct preliminary in...
This $2,308,174 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop new antimicrobial combinations and strategies to combat the threat of drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The key products and services being delivered include: Generating novel mechanistic insights into antibiotic resistance mechanisms and bacterial...
This federal Project Grant award, totaling $299,995, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop a novel class of membrane-modifying antimicrobials, called Anti-Infective Conjugated Electrolytes (ACEs), to combat critical Gram-negative bacterial pathogens and antimicrobial resistance. The key products to be delivered include: Synthesizing and evaluating ~80...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $392,634 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Madison. The grant supports the development of a novel "nanoimmunotherapeutic" approach to combat multidrug-resistant bacterial infections, particularly the ESKAPE pathogens. Key objectives include designing, fabricating, and optimizing a red blood cell membrane-coated,...
This $299,163 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel antimicrobial approach combining endolysin proteins with self-replicating mRNA (RepRNA) delivery using lipid nanoparticles. The Phase I proof-of-concept study has two key objectives: 1) to evaluate whether RepRNA can successfully express a lysin targeting vancomycin-resistant Enterococcus...
This $400,000 Project Grant was awarded on August 15, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports pre-clinical studies to evaluate the prophylactic efficacy of a vaccine targeting two high-priority virulence factors of extraintestinal pathogenic E. coli (ExPEC), a leading cause of antibiotic-resistant infections and mortality worldwide. The studies aim to comprehensively...
This $657,506 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a next-generation pertussis vaccine that elicits mucosal immunity and prevents nasal colonization by the Bordetella pertussis bacteria. The award, with a performance period from Aug 2024 to Jul 2025, will fund experiments to test a subunit vaccine containing newly identified T cell antigens...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $802,798 to develop a novel class of antibiotics called Biamyxins (BMX) to target multidrug-resistant Gram-negative bacterial infections. The 5-year award supports research to identify a qualified lead development candidate and pursue an Investigational New Drug (IND) candidate that can treat infections caused by...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of broadly neutralizing nanobodies for advancing AIDS therapy. The primary goal is to identify and engineer diverse nanobodies that can target multiple sites on the HIV virus envelope protein, with the intent of improving treatment effectiveness and simplifying therapeutic protocols. The...